HENLIUS(02696) Stock Price Today | Quotes & News

HK Stock MarketDetailed Quotes

02696 HENLIUS

Watchlist

40.350
+1.400+3.59%

Market Closed May 2 16:08 CST

21.93BMarket Cap24.75P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Sandoz Group, Henlius Sign Biosimilar License Deal for Ipilimumab Cancer Treatment
MT NewswiresApr 29 12:05 ET
Henlius Biotech Licences Cancer Drug to Sandoz for Global Commercialization
MT NewswiresApr 29 09:16 ET
FOSUN PHARMA (02196) subsidiary HENLIUS signed a Cooperation and License Agreement with Sandoz AG.
FOSUN PHARMA (02196) announced that recently, its subsidiary HENLIUS has entered into an agreement with Sandoz A...
Zhitong FinanceApr 29 08:21 ET
HENLIUS (02696) has signed a licensing agreement with Sandoz for HLX13 (recombinant anti-CTLA-4 fully human monoclonal antibody injection).
HENLIUS (02696) announced that the company has recently entered into a licensing agreement with Sandoz AG, ...
Zhitong FinanceApr 29 05:42 ET
Express News | Shanghai Henlius Biotech Inc - to Receive up to $270 Million in Milestone Payments
ReutersApr 29 05:31 ET
Express News | Shanghai Henlius Biotech Inc - Enters License Agreement With Sandoz for Hlx13
ReutersApr 29 05:31 ET

Comments

Spinee

Jun 25, 2024 10:45

HSI Opens Up 60 pts; LI AUTO & NIO Advance, as HENLIUS Rockets 21%

Hong Kong stocks opened higher in the morning. $Hang Seng Index (800000.HK)$opened 60 points or 0.3% higher at 18,088. $Hang Seng China Enterprises Index (800100.HK)$ opened 22 points or 0.3% higher at 6,463. $Hang Seng TECH Index (800700.HK)$ opened 11 points or 0.3% higher at 3,689.
$FOSUN PHARMA (02196.HK)$ proposed to privatise $HENLIUS (02696.HK)$ at $24.6 per share. HENLIUS opened rocketing 21.3% at $22.85, while FOSUN PHARMA opened lifting 1.2% at...

Moomoo AI

Jan 25, 2024 06:24

Investors' belief in the company's poor revenue performance is likely causing its low P/S ratio. The company's bleak revenue outlook is contributing to its low P/S. These conditions form a barrier for the share price at these levels.

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Moomoo AI

Nov 22, 2023 10:17

Shanghai Henlius Biotech's statutory profit might not fully reflect the company's underlying earning capacity due to unusual item expense. The change from loss to profit is a positive turn for the firm.